Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 14 of 14 for “"Liraglutide"”.

  1. Targeting macrophages GLP-1 receptor pathways as emerging therapies to ameliorate cardiac remodelling associated with diabetes

    … was to study the effects of the GLP-1 analogue, liraglutide, in diabetes with a specific focus on cardiac inflammation. <br/><br/>Based on our previous findings, we initially designed modified GLP-1 peptides to specifically target macrophages. As macrophages express the mannose receptor, we …

    qu-belfast Repository record for Targeting macrophages GLP-1 receptor pathways as emerging therapies to ameliorate cardiac remodelling associated with diabetes (opens in a new tab)

  2. Neuroprotective effects of incretin mimetics upon chronic endoplasmic reticulum (ER) stress : implications for novel therapeutic pathways and opportunities in Alzheimer's disease

    … degeneration. In a recent pilot clinical trial, Liraglutide rescued the decline of the cerebral glucose consumption in Alzheimer’s disease (AD) patients, signifying improved energy metabolism in brain areas previously correlated with cognitive decline and disease progression. However, the exact …

    lancaster Repository record for Neuroprotective effects of incretin mimetics upon chronic endoplasmic reticulum (ER) stress : implications for novel therapeutic pathways and opportunities in Alzheimer's disease (opens in a new tab)

  3. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH-SY5Y cells

    … (GLP-1) analogues; Lixisenatide, Dulaglutide, Liraglutide, and Exenatide (Exendin-4), currently used to treat diabetes, may also be beneficial in the treatment of neurodegenerative conditions such as AD, as they have been shown to exert neuroprotective properties. Research has also suggested …

    lancaster Repository record for The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH-SY5Y cells (opens in a new tab)

  4. Ús de l’ecografia per caracteritzar la distribució del teixit adipós abdominal i el seu impacte en el risc cardiovascular en diferents situacions clíniques i en resposta a diferents règims terapèutics

    … alt risc cardiovascular. - Estudi 3: "Effect of liraglutide in different abdominal fat layers measured by ultrasound. The importance of perirenal fat reduction" (2024) (n=860), en què s'analitza de forma retrospectiva en vida real la reducció de les diferents capes de greix abdominal després de 6 …

    catalunya Repository record for Ús de l’ecografia per caracteritzar la distribució del teixit adipós abdominal i el seu impacte en el risc cardiovascular en diferents situacions clíniques i en resposta a diferents règims terapèutics (opens in a new tab)

  5. Pre-clinical development of cyclodextrin-based nanoparticles for oral delivery of protein/peptide drugs-in vitro and in vivo evaluation

    … Lola insulin) and the GLP-1 analogue named as liraglutide. In the first stage of the preclinical development of these formulations, the fabrication process of the three prototypes containing the different cargos was optimized. The resulting formulations showed suitable physico-chemical …

    cork Repository record for Pre-clinical development of cyclodextrin-based nanoparticles for oral delivery of protein/peptide drugs-in vitro and in vivo evaluation (opens in a new tab)

  6. An evaluation and comparison of current FDA-approved treatments for obesity

    … to develop long-term medications. As a result, liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/ topiramate extended-release became FDA-approved for long-term treatment of obesity. Each drug acts on a specific part of the CNS to modulate appetite and cause …

    bu Repository record for An evaluation and comparison of current FDA-approved treatments for obesity (opens in a new tab)

  7. An investigation into the aggregation of therapeutic peptides through adsorption to primary containers

    … under investigation in this thesis; glucagon, liraglutide, g797 and exendin-4 are all used or on trial for mediating blood glucose levels as a safe and effective treatment for type 2 diabetes. One of the largest drawbacks of peptides is their ability to aggregate and adsorb to surfaces that …

    cambridge Repository record for An investigation into the aggregation of therapeutic peptides through adsorption to primary containers (opens in a new tab)

  8. Extrapancreatic actions of incretin-based therapies on bone in diabetes mellitus

    … incretin-based therapeutics, [D-Ala2 ]GIP and Liraglutide, in streptozotocin-diabetic significantly increased bone matrix properties, indicating recovery of bone strength at the tissue level. The beneficial effects of administration of [D-Ala2 ]GIP�oxyntomodulin on bone health in db/db mice …

    uthm Repository record for Extrapancreatic actions of incretin-based therapies on bone in diabetes mellitus (opens in a new tab)

  9. Identification of a Dual-Action Small Molecule with Potent Anti-diabetic and Anti-obesity Activity

    … effect is comparable with that of liraglutide in blood glycemic control but is better than that of metformin in this overt diabetic model. Collectively, I have identified for the first time, as to the best of our knowledge, that EA could be a dual-action compound that exerts …

    vt Repository record for Identification of a Dual-Action Small Molecule with Potent Anti-diabetic and Anti-obesity Activity (opens in a new tab)

  10. Characterisation and pharmacological regulation of GLP-1-mediated glucose homeostasis

    … GLP-1-based treatments, such as exenatide and liraglutide, have been widely used in T2DM patients. However, in contrast to the well-studied phenomenon of how GLP-1 enhances GSIS, the mechanism of how GLP-1 regulates glucagon secretion is still unclear. Therefore, the aim of this work is to shed …

    cambridge Repository record for Characterisation and pharmacological regulation of GLP-1-mediated glucose homeostasis (opens in a new tab)

  11. Investigation of insulinotropic and cytoprotective effects of selected amphibian skin peptides

    … mice with diet-induced obesity-diabetes, using liraglutide as the positive control. The results obtained revealed that all peptides are of acceptable purity levels. All peptides tested stimulated non-toxic insulin release at concentrations ≥0.01 μM in a dose-dependent manner. Alyeserin-2a …

    wlv Repository record for Investigation of insulinotropic and cytoprotective effects of selected amphibian skin peptides (opens in a new tab)

  12. Complicaciones centrales en un modelo murino de enfermedad de alzheimer y diabetes mellitus: papel de la liraglutida

    … pacientes con EA en el ensayo clínico Evaluating Liraglutide in Alzheimer's Disease (ELAD). En este trabajo hemos compendiado los estudios que analizan el papel de la LRGT en la EA, centrándonos en modelos animales de la enfermedad y su función a nivel cognitivo y en la patología tipo Alzheimer. …

    cadiz Repository record for Complicaciones centrales en un modelo murino de enfermedad de alzheimer y diabetes mellitus: papel de la liraglutida (opens in a new tab)

  13. Uso de medicación con efecto incretina para control glucémico en pacientes adultos hospitalizados con diabetes mellitus tipo 2 entre 2002 y 2018

    Introducción: La diabetes mellitus tipo 2 es una enfermedad con alta prevalencia a nivel mundial y su incidencia aumenta a medida que pasan los años, por lo que es frecuente que los pacientes que se encuentran hospitalizados por diversas causas tengan diabetes como antecedente. En este grupo …

    rosario Repository record for Uso de medicación con efecto incretina para control glucémico en pacientes adultos hospitalizados con diabetes mellitus tipo 2 entre 2002 y 2018 (opens in a new tab)